Conference Presentation Details - Overview
Exploiting the Biology of Renal Cell Carcinoma: From the Laboratory to Practice
Release Date: March 20, 2009|
Expiration Date: March 20, 2010
Feb 25, 2009, Orlando, FL
Lecture Overview
Exploiting the Biology of Renal Cell Carcinoma: From the Laboratory to Practice provides a comprehensive review of current therapeutic standards for advanced/metastatic kidney cancer and an in-depth examination of evolving treatment approaches to the clinical management of this patient population in the era of targeted therapy. In particular, issues important for formulating individualized and optimized patient therapy will be addressed, including the comparative advantages and disadvantages of different agents in different patient subpopulations, the optimal sequencing of targeted therapies, the safety and efficacy of combination therapies, and the potential impact of new agents entering the clinic on existing treatment strategies. This program will feature exciting information on the biologic underpinnings of newer therapies in order to engage the audience in the theme of “from the laboratory to practice.” Case-based clinical scenarios will provide context for interpreting and evaluating the presented data as well as reinforcing the information through its application
This satellite symposium is designed to be of high clinical utility to medical oncologists, surgical oncologists, and radiation oncologists involved in the treatment of renal cell carcinoma. Fellows, oncology physician assistants, oncology nurses, and research nurses with an interest in the treatment of patients with renal cell carcinoma are also invited to participate. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Upon completion of this educational activity, you should be able to:
- Incorporate knowledge regarding the role of the vascular growth factor receptor and PI3K/Akt signaling pathways in the pathobiology of metastatic renal cell carcinoma into the interpretation of efficacy and toxicity data from clinical trials evaluating targeted agents
- Incorporate the proposed treatment algorithm for advanced/metastatic renal cell carcinoma, based on patient risk, treatment history, and evidence from clinical trials, into formulating treatment decisions in daily practice, including the use of FDA-approved targeted agents
- Formulate treatment strategies using the optimal sequence of targeted agents for individualized therapy in refractory/recurrent disease
- Assess the potential roles of second-generation orally available targeted agents still undergoing clinical development in the treatment of renal cell carcinoma and their placement in the proposed treatment algorithm
- Compare the utility of sequential monotherapy to that of combination therapy with targeted agents in maximizing clinical benefit in patients with advanced renal cell carcinoma
Instructions for Participation
- Read the following information before beginning the educational activity.
- Complete the Pretest.
- View and study all Flash video presentations.
- Complete the Posttest.
- Answer the evaluation questions.
- After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
You will be permitted 2 attempts to successfully complete the Posttest.
Accreditation and Credit Designation
Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
You will be asked to login
or create an account.